* Amicus Therapeutics Inc FOLD.OQ reported a quarterly
adjusted
loss of 16 cents per share for the quarter ended in March,
higher than the same quarter last year, when the company
reported EPS of -18 cents. The mean expectation of
eleven analysts for the quarter was for a loss of 7 cents per
share. Wall Street expected results to range from -10 cents
to -3 cents per share.
* Revenue rose 28% to $110.40 million from a year ago;
analysts
expected $111.19 million.
* Amicus Therapeutics Inc's reported EPS for the quarter was
a
loss of 16 cents.
* The company reported a quarterly loss of $48.42 million.
* Amicus Therapeutics Inc shares had fallen by 13.9% this
quarter and lost 28.5% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 27.5%
in the last three months.
* In the last 30 days, one analyst negatively revised an
earnings
estimate
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Amicus
Therapeutics Inc is $20.00
This summary was machine generated from LSEG data May 9 at 01:32
p.m. UTC. All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.07 -0.16 Missed
Dec. 31 2023 -0.06 -0.11 Missed
Sep. 30 2023 -0.08 -0.07 Beat
Jun. 30 2023 -0.12 -0.15 Missed